CD19&CD20 bispecific CAR-T / Hebei Taihe Chunyu Biotech - LARVOL DELTA

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors (clinicaltrials.gov) - P1/2 | N=90 | Recruiting | Sponsor: Tianjin Medical University General Hospital

New P1/2 trial • Acute Myelogenous Leukemia • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia